Last reviewed · How we verify
Uroxatrol (drug)
Uroxatrol is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.
Uroxatrol is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow. Used for Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms.
At a glance
| Generic name | Uroxatrol (drug) |
|---|---|
| Sponsor | New York Prostate Institute |
| Drug class | Alpha-1A adrenergic receptor antagonist |
| Target | Alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
The drug selectively blocks alpha-1A adrenergic receptors, which are predominantly expressed in the prostate and bladder outlet. By antagonizing these receptors, Uroxatrol reduces smooth muscle tone in the prostate and bladder neck, thereby decreasing urethral resistance and improving urinary flow rate in patients with benign prostatic hyperplasia (BPH).
Approved indications
- Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms
Common side effects
- Dizziness
- Headache
- Fatigue
- Retrograde ejaculation
Key clinical trials
- Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions (PHASE1)
- The Bioequivalence Study of Alfuzosin 10 mg Prolong-released Tablets Under Fed Conditions (PHASE1)
- Evaluation of Symptom-specific Goal Achievement (PHASE4)
- Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) (NA)
- Intermittent Catheterization Versus Trial Without Catheter (NA)
- The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients (PHASE4)
- Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (PHASE3)
- Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Uroxatrol (drug) CI brief — competitive landscape report
- Uroxatrol (drug) updates RSS · CI watch RSS
- New York Prostate Institute portfolio CI